FIELD: pharmaceuticals and medicine.
SUBSTANCE: 1 object is the use of a combination containing an antibody to CD19 and venetoclax in the treatment of a patient suffering from non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and/or small cell lymphocytic lymphoma, where the specified antibody to CD19 is administered at least 7 days before the first administration of venetoclax. Object 2 - a method for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and/or small cell lymphocytic lymphoma in a patient, including the introduction of a therapeutically effective amount of the combination.
EFFECT: reducing the risk of developing tumour lysis syndrome (TLS) during combined treatment.
36 cl, 3 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF CD19 ANTIBODY WITH BCL-2 INHIBITOR AND ITS APPLICATION METHODS | 2017 |
|
RU2756405C2 |
| COMBINATIONS AND USE THEREOF | 2016 |
|
RU2767063C2 |
| COMBINATION OF CD19 ANTIBODY AND BRUTON TYROSINE KINASE INHIBITOR AND THEIR APPLICATION | 2016 |
|
RU2756010C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND THEIR USE | 2018 |
|
RU2789150C2 |
| METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DOSES OF ALLOGENEIC T-CELLS WITH CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2776322C2 |
| DOSING STRATEGY REDUCING CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES | 2019 |
|
RU2799529C2 |
